Sequential transformation of mesenchymal stem cells is associated with increased radiosensitivity and reduced DNA repair capacity

Radiation Research

Volumn 179, Issue 6, 2013, Pages 698-706

  Worku, M ^a   Fersht, N ^a   Martindale, C ^a   Funes, J M ^a   Short, S C ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN B; HISTONE H2AX; PROTEIN E6; PROTEIN E7; TELOMERASE REVERSE TRANSCRIPTASE;

APOPTOSIS; ARTICLE; BONE MARROW; CELL CYCLE CHECKPOINT; CELL DIFFERENTIATION; DNA REPAIR; DOUBLE STRANDED DNA BREAK; G2 PHASE CELL CYCLE CHECKPOINT; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; ONCOGENE H RAS; PRIORITY JOURNAL; RADIOSENSITIVITY; RNA INTERFERENCE; S PHASE CELL CYCLE CHECKPOINT; SIGNAL TRANSDUCTION; UPREGULATION;

APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; DNA DAMAGE; DNA REPAIR; HUMANS; MESENCHYMAL STROMAL CELLS; RADIATION TOLERANCE; SIGNAL TRANSDUCTION; TIME FACTORS;

HUMAN PAPILLOMAVIRUS TYPE 16;

EID: 84878697058     PISSN: 00337587     EISSN: 19385404     Source Type: Journal    
DOI: 10.1667/RR2998.1     Document Type: Article

References (30)

1. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3(7):730-7.
2. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003; 100(7):3983-8.
3. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003; 63(18):5821-8.
4. Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, Tang S, et al. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006; 25(12):1696-708.
5. Zhu L, Gibson P, Currle DS, Tong Y, Richardson RJ, Bayazitov IT, et al. Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation. Nature 2009; 457(7229):603-7.
6. Alcantara Llaguno S, Chen J, Kwon CH, Jackson EL, Li Y, Burns DK, et al. Malignant astrocytomas originate from neural stem/ progenitor cells in a somatic tumor suppressor mouse model. Cancer cell 2009; 15(1):45-56.
7. Correa P, Houghton J. Carcinogenesis of Helicobacter pylori. Gastroenterology 2007; 133(2):659-72.
8. Eramo A, Ricci-Vitiani L, Zeuner A, Pallini R, Lotti F, Sette G, et al. Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ 2006; 13(7):1238-41.
9. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444(7120):756-60.
10. Blazek ER, Foutch JL, Maki G. Daoy medulloblastoma cells that express CD133 are radioresistant relative to CD133-cells, and the CD133+ sector is enlarged by hypoxia. Int J Radiat Oncol Biol Phys 2007; 67(1):1-5.
11. Garvalov BK, Acker T. Cancer stem cells: a new framework for the design of tumor therapies. J Mol Med (Berl). 2011; 89(2): 95-107.
12. Cheng L, Wu Q, Huang Z, Guryanova OA, Huang Q, Shou W, et al. L1CAM regulates DNA damage checkpoint response of glioblastoma stem cells through NBS1. Embo J 2011; 30(5): 800-13.
13. McCord AM, Jamal M, Williams ES, Camphausen K, Tofilon PJ. CD133+ glioblastoma stem-like cells are radiosensitive with a defective DNA damage response compared with established cell lines. Clin Cancer Res 2009; 15(16):5145-53.
14. Wang J, Sakariassen PO, Tsinkalovsky O, Immervoll H, Boe SO, Svendsen A, et al. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer 2008; 122(4):761-8.
15. Ogden AT, Waziri AE, Lochhead RA, Fusco D, Lopez K, Ellis JA, et al. Identification of A2B5+CD133-tumor-initiating cells in adult human gliomas. Neurosurgery 2008; 62(2):505-14; discussion 14-5.
16. Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, Milde T, et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133-metastatic colon cancer cells initiate tumors. J Clin Invest 2008; 118(6):2111-20.
17. Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner PJ, et al. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 2007; 67(9):4010-5.
18. Barrett LE, Granot Z, Coker C, Iavarone A, Hambardzumyan D, Holland EC, et al. Self-renewal does not predict tumor growth potential in mouse models of high-grade glioma. Cancer cell 2012; 21(1):11-24.
19. Mihatsch J, Toulany M, Bareiss PM, Grimm S, Lengerke C, Kehlbach R, et al. Selection of radioresistant tumor cells and presence of ALDH1 activity in vitro. Radiother Oncol: J Europ Soc Ther Radiol Oncol 2011; 99(3):300-6.
20. Facchino S, Abdouh M, Chatoo W, Bernier G. BMI1 confers radioresistance to normal and cancerous neural stem cells through recruitment of the DNA damage response machinery. J Neuroscie J Soc Neurosci 2010; 30(30):10096-111.
21. Magee JA, Piskounova E, Morrison SJ. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer cell. 2012; 21(3):283-96.
22. Mannino M, Chalmers AJ. Radioresistance of glioma stem cells: intrinsic characteristic or property of the 'microenvironment-stem cell unit'? Molecular Oncol 2011; 5(4):374-86.
23. Funes JM, Quintero M, Henderson S, Martinez D, Qureshi U, Westwood C, et al. Transformation of human mesenchymal stem cells increases their dependency on oxidative phosphorylation for energy production. Proc Natl Acad Sci U S A 2007; 104(15): 6223-8.
24. Serakinci N, Christensen R, Graakjaer J, Cairney CJ, Keith WN, Alsner J, et al. Ectopically hTERT expressing adult human mesenchymal stem cells are less radiosensitive than their telomerase negative counterpart. Exp Cell Res 2007; 313(5): 1056-67.
25. Kampinga HH, Van Waarde-Verhagen MA, Van Assen-Bolt AJ, Nieuwenhuis B, Rodemann HP, Prowse KR, et al. Reconstitution of active telomerase in primary human foreskin fibroblasts: effects on proliferative characteristics and response to ionizing radiation. Int J Radiat Biol 2004; 80(5):377-88.
26. Halazonetis TD, Gorgoulis VG, Bartek J. An oncogene-induced DNA damage model for cancer development. Science 2008; 319(5868):1352-5.
27. Bartek J, Bartkova J, Lukas J. DNA damage signalling guards against activated oncogenes and tumour progression. Oncogene 2007; 26(56):7773-9.
28. Stevens C, Smith L, La Thangue NB. Chk2 activates E2F-1 in response to DNA damage. Nat Cell Biol 2003; 5(5):401-9.
29. Takai H, Naka K, Okada Y, Watanabe M, Harada N, Saito S, et al. Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription. Embo J 2002; 21(19):5195-205.
30. Squatrito M, Brennan CW, Helmy K, Huse JT, Petrini JH, Holland EC. Loss of ATM/Chk2/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas. Cancer cell 2010; 18(6):619-29.